Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.02
-0.28 (-4.44%)
At close: May 28, 2026
Market Cap1.47B +1.9%
Revenue (ttm)1.45B -4.6%
Net Income154.02M -0.1%
EPS0.63 -16.9%
Shares Out 241.52M
PE Ratio9.70
Forward PEn/a
Dividend0.07 (1.05%)
Ex-Dividend DateJun 17, 2026
Volume21,200
Open6.11
Previous Close6.30
Day's Range6.02 - 6.17
52-Week Range5.91 - 16.29
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 18, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 1,794
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2566
Full Company Profile

Financial Performance

In 2025, HKG:2566's revenue was 1.31 billion, a decrease of -4.59% compared to the previous year's 1.37 billion. Earnings were 138.41 million, a decrease of -0.14%.

Financial numbers in CNY Financial Statements